PGRMC1 and neoplasm: PGRMC1 knockdown is associated with increased chemosensitivity of human endometrial xenograft tumors to doxorubicin, paclitaxel and carboplatin, followed by a fourfold decrease in the tumor volume in comparison with PGRMC1-intact controls [110].